AI News about creative medical technology

Creative Medical Technology outlines 2025 losses, trials

Creative Medical Tech Faces 2025 Losses Amid FDA Trials Creative Medical Technology reported significant 2025 operating losses with modest cash reserves of $7.2 million and minimal revenue. However, the company is advancing FDA-cleared trials including Fast Track CELZ-201-DDT and iPSC/AI partnerships targeting diabetes, back pain, and other regenerative medicine indications.